Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

PHASE2TerminatedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

September 23, 2015

Primary Completion Date

March 15, 2018

Study Completion Date

February 4, 2020

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

IFNα-Kinoid

OTHER

Placebo

OTHER

ISA 51 VG

Trial Locations (101)

13

Research Site, Lima

27

Research Site, Lima

29

Research Site, Lima

31

Research Site, Lima

33

Research Site, Lima

41

Research Site, Lima

100

Research Site, Taipei

112

Research Site, Taipei

114

Research Site, Taipei

1000

Research Site, Manila

1007

Research Site, Tunis

1008

Research Site, Tunis

1011

Research Site, Lausanne

1102

Research Site, Quezon

1200

Research Site, Brussels

2025

Research Site, Chisinau

2026

Research Site, Chisinau

3029

Research Site, Sfax

4000

Research Site, Sousse

6000

Research Site, Cebu

8000

Research Site, Davao City

10000

Research Site, Zagreb

10400

Research Site, Bangkok

10700

Research Site, Bangkok

13003

Research Site, Marseille

14059

Research Site, Berlin

20122

Research Site, Milan

27100

Research Site, Pavia

28210

Research Site, Charlotte

32810

Research Site, Orlando

33126

Research Site, Miami

33134

Research Site, Miami

33136

Research Site, Miami

33309

Research Site, Fort Lauderdale

33600

Research Site, Pessac

33614

Research Site, Tampa

33901

Research Site, Fort Myers

34295

Research Site, Montpellier

37000

Research Site, León

37134

Research Site, Verona

40138

Research Site, Bologna

40201

Research Site, Taichung

40402

Research Site, Taichung

44130

Research Site, Guadalajara

44160

Research Site, Guadalajara

44280

Research Site, Guadalajara

44500

Research Site, Guadalajara

44690

Research Site, Guadalajara

55131

Research Site, Mainz

56126

Research Site, Pisa

59037

Research Site, Lille

61231

Research site, Bad Nauheim

62290

Research Site, Cuernavaca

67098

Research site, Strasbourg

72205

Research Site, Little Rock

73104

Research Site, Oklahoma City

75679

Research Site, Paris

78731

Research Site, Austin

80639

Research Site, Munich

90017

Research Site, Los Angeles

92037

Research Site, La Jolla

110221

Research Site, Bogotá

111211

Research Site, Bogotá

119333

Research Site, Moscow

130625

Research Site, Hanover

191015

Research Site, Saint Petersburg

196066

Research Site, Saint Petersburg

250252

Research Site, Zipaquirá

410054

Research Site, Saratov

454076

Research Site, Chelyabinsk

460018

Research Site, Orenburg

620102

Research Site, Yekaterinburg

644024

Research Site, Omsk

644111

Research Site, Omsk

650000

Research Site, Kemerovo

650066

Research Site, Kemerovo

680003

Research Site, Bucaramanga

7500710

Research Site, Santiago

7501126

Research Site, Santiago

7510047

Research Site, Santiago

7510186

Research Site, Santiago

7640881

Research Site, Santiago

Unknown

Research Site, Buenos Aires

Research Site, Sousse

050034

Research Site, Medellín

080002

Research Site, Barranquilla

0159

Research Site, Tbilisi

0160

Research Site, Tbilisi

0186

Research Site, Tbilisi

00161

Research Site, Rome

06700

Research Site, México

07760

Research Site, México

41-902

Research Site, Bytom

31-121

Research Site, Krakow

61-397

Research Site, Poznan

41-200

Research Site, Sosnowiec

71 - 252

Research Site, Szczecin

02-691

Research Site, Warsaw

52-416

Research Site, Wroclaw

07061

Research Site, Seoul

07345

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neovacs

INDUSTRY

NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter